Department of Radiology, Austin Health, 145 Studley Road, Heidelberg, Melbourne, VIC 3084, Australia.
Radiographics. 2011 Oct;31(6):1547-68. doi: 10.1148/rg.316115528.
The use of gadolinium-based hepatocyte-specific contrast agents (HSCAs) has increased markedly since their introduction, and hepatocellular phase imaging performed with an HSCA is now a key part of the standard magnetic resonance (MR) imaging work-up for focal liver lesions. An understanding of the mechanisms of action of HSCAs helps ensure their effective use. The optimal delay for hepatocellular phase image acquisition differs between the two currently available HSCAs, gadoxetic acid and gadobenate dimeglumine, and MR imaging protocols must be adjusted accordingly. In addition, familiarity with typical and atypical appearances of benign and malignant focal liver lesions at HSCA-enhanced hepatocellular phase MR imaging, along with knowledge of the processes that are most likely to produce atypical appearances, is required to achieve optimal diagnostic accuracy.
自从钆基肝细胞特异性对比剂（HSCAs）问世以来，其应用显著增加，现在使用 HSCAs 进行肝细胞期成像已成为局灶性肝脏病变标准磁共振（MR）成像检查的重要组成部分。了解 HSCAs 的作用机制有助于确保其有效应用。目前可用的两种 HSCAs，即钆塞酸二钠和钆贝葡胺，其肝细胞期图像采集的最佳延迟时间不同，因此必须相应调整 MR 成像方案。此外，熟悉 HSCAs 增强肝细胞期 MR 成像时良性和恶性局灶性肝脏病变的典型和非典型表现，以及了解最有可能产生非典型表现的过程，对于实现最佳诊断准确性至关重要。
